HEPSERA HEPOVIR ADEFO ADVIR HEPSERA B-AD EFFO-B ANOVIR ANOVIR HAPTIC HI-VIR TONAVIR TONAVIR HEPTROL ADEFASS ADEWEL ADROWIN HAPOTIN VIRGOCIL HEPBI HEPIRAL VADEFO Adefo ADGEN

Dose: 10 mg/day
Single Dose: 10 (10)
Frequency: As recommended.
Route: PO
Instructions: Significantly increased drug exposures were seen when Adefovir dipivoxil was administered to adult patients with renal impairment. Therefore, the dosing interval of Adefovir dipivoxil should be adjusted in adult patients with baseline creatinine clearance

Adefovir Dipivoxil also known as Adefovir, Adefovir, Adefovir. . It is of Synthetic origin. It belongs to DNA polymerase inhibitor pharmacological group on the basis of mechanism of action. The Molecular Weight of Adefovir Dipivoxil is 501.48.

Adefovir Dipivoxil is contraindicated in conditions like Hypersensitivity,Breast feeding.

The severe or irreversible adverse effects of Adefovir Dipivoxil, which give rise to further complications include Renal failure.The symptomatic adverse reactions produced by Adefovir Dipivoxil are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Diarrhea, Abdominal pain, Dyspepsia, Asthenia, Nausea and vomiting, Hypophosphatemia, dyspepsia.

Adefovir Dipivoxil is primarily indicated in conditions like Viral hepatitis.

No data regarding the interactions of Adefovir Dipivoxil was found.

Abnormalities of AST(SGOT) and ALT(SGPT) values Serum creatinin raised

Drug should not be given to Pregnant Mothers, patients suffering from Kidney dysfunction, patients suffering from Liver Malfunction, and Geriatrics.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Tabs Store Between 15°C-30°C.

Patients should be monitored closely for adverse events when Adefovir dipivoxil is co-administered with drugs that are excreted renally or with other drugs known to affect renal function. Hepatic function should be monitored at repeated intervals with both clinical and laboratory follow-up for at least several months in patients who discontinue Adefovir dipivoxil. It is important to monitor renal function for all patients during treatment. Caution should be exercised when prescribing Adefovir dipivoxil to adolescents with underlying renal dysfunction, and renal function in these patients should be closely monitored. Particular caution should be exercised when administering nucleoside analogs to any patient with known risk factors for liver disease. Obtaining HIV antibody testing prior to starting Adefovir dipivoxil is important.